Erytech submits EMA marketing authorisation application for Graspa to treat acute lymphoblastic leukaemia

14 September 2015 - Erytech Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other ...

Read more →

Amgen submits application to FDA for new delivery option for monthly administration of Repatha (evolocumab)

11 September 2015 - Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking ...

Read more →

AbbVie's Humira (adalimumab) receives U.S. FDA approval for moderate to severe hidradenitis suppurativa

10 September 2015 - AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Humira ...

Read more →

U.S. FDA accepts first digital medicine new drug application for Otsuka and Proteus Digital Health

10 September 2015 - Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health today announced that the United States Food and Drug ...

Read more →

FDA grants fast track designation for MediciNova's MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis

10 September 2015 - MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the ...

Read more →

U.S. FDA grants priority review to Takeda's ixazomib citrate for patients with relapsed/refractory multiple myeloma

9 September 2015 - Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted priority ...

Read more →

FDA grants Genentech’s alectinib priority review for specific type of ALK-positive lung cancer

9 September 2015 - Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) ...

Read more →

Alexion receives notification of PDUFA date extension for Kanuma (sebelipase alfa)

4 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription ...

Read more →

US FDA grants breakthrough therapy designation for Roche’s investigational medicine ACE910 for people with haemophilia A with factor VIII inhibitors

4 September 2015 - Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ...

Read more →

US FDA approves expanded indication for Brilinta to include long-term use in patients with a history of heart attack

3 September 2015 - AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at ...

Read more →

Acadia Pharmaceuticals submits new drug application for Nuplazid for the treatment of Parkinson’s disease psychosis

3 September 2015 - Acadia Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialisation of innovative medicines to address ...

Read more →

U.S. FDA approves update of Simponi Aria (golimumab for infusion) label to include improvement in both physical and emotional measures of health when treating moderately to severely active rheumatoid arthritis

4 September 2015 - Janssen Biotech, Inc. announced today the approval of a U.S. Food and Drug Administration (FDA) Supplemental ...

Read more →

Novartis launches first U.S. 'biosimilar' drug at 15 percent discount

3 September 2015 - Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first ...

Read more →

Sandoz launches Zarxio (filgrastim-sndz), the first biosimilar in the United States

3 September 2015 - Sandoz, a Novartis company, announced today that Zarxio (filgrastim-sndz) is now available in the United States. Zarxio ...

Read more →

Allergan announces FDA approval of updated label for Teflaro (ceftaroline fosamil)

2 September 2015 - Allergan plc. today announced the U.S. Food and Drug Administration (FDA) has approved the company's supplemental new ...

Read more →